Korro Bio, Inc.

NASDAQ•KRRO

CEO: Mr. Nessan Bermingham Ph.D.

板块: Healthcare

行业: Biotechnology

上市日期: 2019-10-03

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

联系方式

One Kendall Square, Building 600-700 Suite 6-401, Cambridge, MA, 02139, United States

617-468-1999

www.korrobio.com

市值

$108.11M

市盈率 (TTM)

-1.2

17.5

股息率

52周最高

$55.89

52周最低

$5.20

52周范围

12%

排名59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

基于 8 年期基本面

疲弱 • 2.2 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2018-2025

财务仪表盘

Q3 2025 数据

营业收入

$1.09M+0.00%

近4季度走势

每股收益

-$1.92-15.04%

近4季度走势

自由现金流

-$17.35M-17.26%

近4季度走势

2025 Q3 财报亮点

核心亮点

Collaboration Revenue Recognized Nine months collaboration revenue reached $5.1M, compared to zero recognized in the prior nine months period.

R&D Expenses Increased Research and development expenses rose $7.9M to $54.6M for nine months, funding pipeline advancement.

KRRO-121 Candidate Nominated Nominated KRRO-121 for UCD/HE treatment; planning first-in-human regulatory filing in second half 2026.

Cash Runway Extended Cash, cash equivalents, and marketable securities totaled $102.5M, funding operations into second half 2027.

关注风险

KRRO-110 Program Pivoting KRRO-110 failed to meet AATD protein goals; pivoting delivery method, which may cause development delays.

Increased Net Loss Nine months net loss widened to $67.2M from $62.4M; requires substantial future capital infusion.

Workforce Reductions Impact Implemented two workforce reductions (May and November 2025); future expansion efforts face integration challenges.

Novo Nordisk Collaboration Paused Novo Nordisk collaboration paused for 12 months starting November 2025, suspending expected revenue recognition.

前瞻展望

KRRO-121 Clinical Trial Filing Plan to submit regulatory filing for KRRO-121 first-in-human trial during the second half of 2026.

AATD Candidate Nomination Prioritizing GalNAc-conjugated AATD program; expect to nominate a development candidate during 2026.

Continued High R&D Spending Expect substantial increase in R&D expenses to advance pipeline through clinical development stages.

Pursuing Additional Financing Will pursue additional cash resources through public or private equity offerings, collaborations, or debt financings.

同行对比

营业收入 (TTM)

AMRN

$183.87M

-19.6%

CLLS

$75.27M

+158.9%

ADCT

$73.55M

+3.8%

毛利率 (最新季度)

ALT

57207.7%

-299200.0pp

AMRN

119.2%

+7.3pp

KRRO

100.0%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
RAPT	$959.26M	-14.8	-61.8%	1.6%
ANNX	$727.14M	-4.4	-92.3%	11.8%
ADCT	$594.61M	-5.1	66.2%	135.9%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

-21.7%

增长承压

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年3月17日

每股收益:-$1.93

营业收入:$425.00K

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据